Business
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.” Recent Achievements and Upcoming Milestones Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026.The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026.Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human proof-of-concept data by the end of 2026.Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial with topline data results available in 2027. Upcoming Events Editas Medicine plans to participate in the following investor event: Barclays 28th Annual Global Healthcare ConferenceFormat: Fireside Chat Date: March 12, 2026 Time: 8:30 ...